Effectiveness and Safety of HPV Vaccines for Women
Author Information
Author(s): Lu Beibei, Kumar Ambuj, Castellsagué Xavier, Giuliano Anna R
Primary Institution: H. Lee Moffitt Cancer Center and Research Institute
Hypothesis
The study aims to assess the efficacy and safety of prophylactic HPV vaccines against cervical cancer precursor events in women.
Conclusion
Prophylactic HPV vaccines are safe, well tolerated, and highly effective in preventing persistent infections and cervical diseases associated with vaccine-HPV types among young females.
Supporting Evidence
- Seven unique trials enrolling 44,142 females were included.
- Vaccines were highly efficacious against 6-month persistent infection with HPV 16 and 18.
- The risk of serious adverse events did not differ significantly between vaccine and control groups.
- Prophylactic HPV vaccines demonstrated a statistically significant reduction in CIN2+ incidence.
Takeaway
HPV vaccines help protect girls and women from getting sick from certain types of viruses that can cause cervical cancer.
Methodology
The study conducted a systematic review and meta-analysis of randomized-controlled trials of HPV vaccines, synthesizing efficacy data using fixed-effect models.
Potential Biases
There was a potential for publication bias, but it was not statistically significant.
Limitations
Data on abnormal pregnancy outcomes were underreported, and the efficacy results may not apply to more mature, sexually active female populations.
Participant Demographics
Participants were non-pregnant women aged 15 to 44 with limited lifetime sexual partners and no history of abnormal Pap smears.
Statistical Information
Confidence Interval
95% CI: 0.01-0.11
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website